James F. Cummings - 17 Mar 2023 Form 4 Insider Report for Vaxart, Inc. (VXRT)

Role
Chief Medical Officer
Signature
/s/ Edward Berg, Attorney-in-Fact for James Cummings
Issuer symbol
VXRT
Transactions as of
17 Mar 2023
Transactions value $
$0
Form type
4
Filing time
21 Mar 2023, 19:53:51 UTC
Previous filing
30 Mar 2022
Next filing
20 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VXRT Common Stock Award $0 +45K +102.86% $0.00 88.8K 17 Mar 2023 Direct F1
transaction VXRT Common Stock Award $0 +59.4K +66.87% $0.00 148K 17 Mar 2023 Direct F1
transaction VXRT Common Stock Award $0 +90K +60.77% $0.00 238K 17 Mar 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VXRT Stock Option (right to buy) Award $0 +205K $0.00 205K 17 Mar 2023 Common Stock 205K $0.78 Direct F2
transaction VXRT Stock Option (right to buy) Award $0 +410K $0.00 410K 17 Mar 2023 Common Stock 410K $0.78 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023.
F2 The shares subject to this stock option shall fully vest on December 8, 2023.
F3 Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of February 2, 2023, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date.
F4 The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on February 2, 2024, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on February 2, 2027.

Remarks:

Exhibit 24 - Power of Attorney